<DOC>
	<DOCNO>NCT00857649</DOCNO>
	<brief_summary>The primary objective study examine efficacy memantine cognition behavioural symptom outpatient moderate severe dementia Alzheimer 's type .</brief_summary>
	<brief_title>Efficacy Safety Memantine Moderate Severe Alzheimer 's Disease</brief_title>
	<detailed_description>Memantine moderate affinity , uncompetitive N-methyl-D-aspartate ( NMDA ) receptor antagonist . Pre-clinical study demonstrate memantine decrease neuronal toxicity associate excessive glutamate release calcium overload neuron . Results clinical trial patient moderate severe Alzheimer 's Disease ( AD ) demonstrate memantine 's efficacy safety show positive treatment effect cognitive , global functional decline . This 24-week randomised , double-blind , placebo-controlled , multicentre study examines effect memantine 20 mg , administer daily , cognitive behavioural symptom outpatient diagnose moderate severe AD significant psychopathology .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<criteria>Outpatients : primary diagnosis probable Alzheimer 's Disease ( AD ) accord National Institute Neurological Communicative Disorders Stroke Alzheimer 's Disease Related Disorders Association ( NINDSADRDA ) criterion , Diagnostic Statistical Manual Mental Disorders , 4th edition , text revise ( DSM IV TR ) criteria dementia Alzheimer 's type moderate severe dementia , define Mini Mental State Examination ( MMSE ) total score &gt; =5 &lt; =15 screen . Before substantial protocol amendment SA04 ( date 7 October 2004 ) implement , MMSE total score range screen &gt; =8 &lt; =18 . Substantial protocol amendment SA07 ( date 4 September 2009 ) allow patient previously MMSE score 16 17 rescreened &gt; 6 month initial screening , document evidence cognitive decline , enrol study Neuropsychiatric Inventory ( NPI ) total score &gt; =13 NPI agitation/aggression subitem score &gt; =1 screen baseline vascular dementia modify Hachinski Ischaemia Scale score &gt; 4 screen Evidence clinically significant active disease , evidence neurological disorder , previous treatment memantine</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Alzheimer 's Disease</keyword>
</DOC>